U.S. Markets close in 1 hr 39 mins

Petros Pharmaceuticals, Inc. (PTPI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7610-0.0458 (-5.68%)
As of 04:00PM EDT. Market open.

Petros Pharmaceuticals, Inc.

1185 Avenue of the Americas
Suite 249
New York, NY 10036
United States

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Mr. John D. ShulmanExec. ChairmanN/AN/A1963
Mr. Fady Boctor M.B.A.Principal Exec. Officer, Pres & Chief Commercial Officer519.48kN/A1978
Mr. Mitchell S. Arnold M.B.A.VP of Fin. & Chief Accounting Officer365.92kN/A1964
Mr. Robert WeinsteinInterim Chief Financial OfficerN/AN/A1960
Mr. Keith F. LavanAdvisorN/AN/A1964
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Corporate Governance

Petros Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.